Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, AVM Biotechnology is raising $14,720,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Theresa Deisher played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AVM Biotechnology

Founded in 2008, AVM Biotechnology is dedicated to the discovery, development, and commercialization of stem cell-enabling technologies for regenerative medicine, immuno-oncology and fully human biologics applications. Between 2012 and 2017, AVM Biotechnology has successfully raised $14 million from friends and family. With global robust intellectual property (IP) and broad patent claims, AVM’s lead small molecule AVM0703 is ready for Phase 1/2 clinical trials in 2019.

To learn more about AVM Biotechnology, visit http://avmbiotech.com/

Contact:
Theresa Deisher, Chief Executive Officer
206-906-9922
tdeisher@avmbiotech.com
https://www.linkedin.com/in/theresa-deisher-36b9818/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved